CSL (ASX:CSL) crowdsourcing ideas to optimise plasma technology

Company News

by Michael Luu

Biotechnology researcher CSL (ASX:CSL) has kickstarted a crowdsourcing campaign to generate ideas for optimising the company’s plasma technology.

Startup incubator Cicada Innovations is facilitating the medical company’s "research challenge". The competition offers $55,000 worth of rewards for the most innovative life-saving approaches to their immunoglobulin product, extracted from collected plasma. Plasma collections’ output is considered vital to the company’s sales and earnings in the coming year.

Shares in CSL (ASX:CSL) are trading 0.22 per cent higher at $265.25


Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.